Castle Biosciences(US:CSTL)2026-02-26 22:30Financial Data and Key Metrics Changes - In Q4 2025, Castle Biosciences reported total revenue of $87 million, leading to a full-year revenue of $344.2 million, exceeding guidance [5][19] - Full-year revenue growth, excluding DecisionDx-SCC and IDgenetix, was approximately 34% [5] - Adjusted EBITDA for Q4 was $11.5 million, down from $21.3 million in Q4 2024, and for the full year, it was $44 million compared to $75 million in 2024 [25][26] Business Line Data and Key Metrics Changes - DecisionDx-Melanoma generated 39,083 test reports in 2025, reflecting a 9% year-over-year growth [9] - TissueCypher achieved 39,014 test reports in 2025, representing an 86% increase from 2024 [10] - Total test report volume for the year was 105,053, a 37% increase compared to 2024 [6] Market Data and Key Metrics Changes - The company noted a patient penetration of approximately 31% for DecisionDx-Melanoma and 11% for TissueCypher by the end of 2025 [10][12] - The dermatology market is expected to expand significantly with the launch of the AdvanceAD-Tx test, which is anticipated to contribute materially to revenue in 2027 or 2028 [14] Company Strategy and Development Direction - Castle Biosciences aims to enhance patient care through innovative tests and has outlined a growth strategy that includes near-term, mid-term, and long-term initiatives [8][15] - The company plans to continue evaluating M&A opportunities that align with its strategic goals, focusing on tests that are near or at market and reimbursement [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of DecisionDx-Melanoma and TissueCypher, citing strong clinician adoption and ongoing clinical evidence [10][12] - The company anticipates total revenue for 2026 to be between $340 million and $350 million, reflecting mid to high teens growth over 2025 [19] Other Important Information - The gross margin for Q4 2025 was 76.3%, slightly up from 76.2% in Q4 2024, while the full-year gross margin was 69.2%, down from 78.5% in 2024 [20] - The company had cash equivalents and marketable securities of $299.5 million as of December 31, 2025 [27] Q&A Session Summary Question: Update on DecisionDx-Melanoma and NCCN guidelines - Management highlighted that the NCCN guidelines did not change the threshold for sentinel lymph node biopsy, maintaining a 5% standard, and noted the importance of their test in potentially avoiding unnecessary procedures [32][33] Question: FDA submission timeline for DecisionDx-Melanoma - The company is preparing a de novo 510(k) submission, expecting acceptance by the end of 2026 or early 2027, which could enhance adoption and reimbursement discussions [38][39] Question: Strategy for AdvanceAD-Tx test - The sales team is focusing on maintaining momentum with DecisionDx-Melanoma while gradually introducing AdvanceAD-Tx, with a planned shift in sales focus as adoption increases [45][48] Question: TissueCypher sales team and growth - The company continues to expand the TissueCypher sales team and anticipates further growth through both existing and new clinician adoption [52][56] Question: Expectations for melanoma volume growth in 2026 - Management expects mid to high single-digit volume growth for melanoma tests in 2026, supported by strong clinician engagement [64][65]